MENG-YAO LUMEI-HWEI CHANGKEH-SUNG TSAIChen D.-S.2020-12-162020-12-1619990264-410Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-0032889379&doi=10.1016%2fS0264-410X%2898%2900149-2&partnerID=40&md5=85596adf86ed56eec96b906bfcd79006https://scholars.lib.ntu.edu.tw/handle/123456789/526490Inactivated hepatitis A virus (HAV) vaccine was administered to 55 healthy seronegative adult volunteers to evaluate the immunogenicity and adverse reactions of two doses of HAV vaccination (25 units) in comparison with a three-dose regimen. The volunteers were randomly assigned to receive one of the two regimens: 26 were vaccinated with two doses at 0 and 24 weeks (Group 1), and 29 were vaccinated with three doses at 0, 2, and 24 weeks (Group 2). The vaccine was well tolerated and there was no serious adverse reaction. In both groups, the seroconversion rate was 100% at week 28. At week 52, all remained positive for anti-HAV regardless of a two- or three- dose regimen. No statistically significant difference in seroconversion rates and geometric mean titers could be demonstrated between the two groups. Thus, the two-dose regimen may be favorable to save cost and time for active immunization against hepatitis A.[SDGs]SDG3hepatitis a vaccine; adult; antibody titer; article; clinical trial; controlled study; cost effectiveness analysis; diarrhea; dose response; drug efficacy; drug tolerability; edema; fatigue; female; fever; headache; hepatitis a; human; human experiment; immune response; immunogenicity; immunomodulation; immunostimulation; injection pain; intramuscular drug administration; male; nausea; normal human; priority journal; randomized controlled trial; seroconversion; vaccination; vertigo; vomiting; Adult; Dose-Response Relationship, Immunologic; Female; Hepatitis A Antibodies; Hepatitis A Vaccines; Hepatitis Antibodies; Hepatovirus; Humans; Immunization Schedule; Male; Transaminases; Viral Hepatitis Vaccinesjournal article10.1016/S0264-410X(98)00149-2100786042-s2.0-0032889379